Heart failure blood tests help answer different parts of the diagnostic puzzle. BNP or NT-proBNP can show that the heart is under increased wall stress, while kidney, electrolyte, blood-count, iron, thyroid, glucose, lipid, and liver tests look for contributors, complications, and treatment-safety concerns. No single result confirms heart failure, defines its stage, or replaces a clinician’s evaluation, ECG, and cardiac imaging.
Important: New or severe shortness of breath, chest pressure or pain, fainting, confusion, blue or gray lips, or sudden worsening symptoms require urgent medical evaluation. Direct-access laboratory testing is not an emergency service and should not delay care.
Knowledge Center: Heart Health Blood Tests · Complete Guide to Lab Tests and Blood Work · How to Read Lab Results · Direct Access Lab Testing
Heart failure is a clinical syndrome in which a structural or functional heart abnormality prevents the cardiovascular system from meeting the body’s needs without increased filling pressures. A diagnosis usually combines characteristic symptoms or signs with objective evidence such as congestion on examination or imaging, abnormal cardiac structure or function, and—in the right context—elevated natriuretic peptides.1
Heart failure is not always a simple “weak pump.” Some people have a reduced left-ventricular ejection fraction, while others develop heart failure despite a preserved ejection fraction. Valve disease, prior heart injury, persistent high blood pressure, rhythm disorders, cardiomyopathy, and infiltrative or metabolic disease are among the many possible causes.
Typical symptoms include shortness of breath during activity or while lying flat, reduced exercise tolerance, fatigue, swelling in the legs or abdomen, rapid weight gain from fluid, cough, and waking at night short of breath. These symptoms are important but not specific: lung disease, anemia, kidney disease, thyroid disease, infection, obesity, and deconditioning can look similar.
Core idea: Ejection fraction is important, but it is only one part of the picture. Symptoms, examination findings, biomarkers, imaging, underlying cause, disease stage, and trajectory all matter.
“Stage” and “class” are not interchangeable. ACC/AHA/HFSA Stages A–D describe how heart failure develops and a person’s overall clinical status. The New York Heart Association (NYHA) functional classification describes how much symptoms limit physical activity. NYHA classification is generally applied to people with symptomatic or advanced heart failure—Stages C and D. BNP, NT-proBNP, or any other single blood test does not determine either a stage or a functional class.2
| Stage | Current term | What it means | Where laboratory testing fits |
|---|---|---|---|
| Stage A | At risk for heart failure | Risk factors are present, but there are no heart-failure symptoms and no identified structural or functional heart disease. Examples include hypertension, diabetes, obesity, coronary disease, cardiotoxic exposure, or familial cardiomyopathy risk. | Testing may identify or monitor risk factors such as glucose, A1C, lipids, kidney function, and urine albumin. These tests assess contributors; they do not diagnose heart failure. |
| Stage B | Pre-heart failure | There are no current or previous heart-failure symptoms, but structural heart disease, abnormal filling pressures, or other objective evidence suggests pre-heart failure. | Biomarkers may add context, but imaging and clinical evaluation are central. An abnormal BNP or NT-proBNP alone should not automatically assign Stage B. |
| Stage C | Symptomatic heart failure | Structural heart disease is accompanied by current or previous symptoms such as breathlessness, swelling, fatigue, reduced exercise tolerance, or difficulty lying flat. | BNP or NT-proBNP may support evaluation. Kidney, electrolyte, iron, thyroid, blood-cell, metabolic, and liver testing can identify contributors, complications, and monitoring concerns. |
| Stage D | Advanced heart failure | Symptoms substantially disrupt daily life, persist despite usual treatment, or lead to recurrent hospitalization and advanced-care needs. | Laboratory testing helps assess congestion, organ effects, and treatment safety, but this stage requires specialist management rather than direct-access testing alone. |
The stage framework is a continuum, not a score generated by a laboratory report. Stage A focuses on risk; Stage B adds objective pre-heart-failure findings without symptoms; Stage C includes current or prior symptoms; and Stage D describes advanced disease that markedly affects daily life.2
| NYHA class | Functional meaning |
|---|---|
| Class I | No limitation of ordinary physical activity. Ordinary activity does not cause excessive fatigue, palpitations, or shortness of breath. |
| Class II | Slight limitation. The person is comfortable at rest, but ordinary physical activity produces symptoms. |
| Class III | Marked limitation. The person is comfortable at rest, but less-than-ordinary activity produces symptoms. |
| Class IV | Heart-failure symptoms may occur at rest, and physical activity increases discomfort. |
NYHA class can change as symptoms improve or worsen. It is a clinician-assigned functional assessment based primarily on symptom-related activity limitation—not a laboratory result. A person’s ACC/AHA/HFSA stage and NYHA class may therefore convey different but complementary information.2
BNP and NT-proBNP reflect myocardial wall stress. A higher result does not automatically establish heart failure or determine its stage. Kidney dysfunction, atrial fibrillation, older age, and other cardiovascular or pulmonary conditions can raise natriuretic peptides. Obesity can produce unexpectedly low results. Stage assignment requires medical history, symptoms, examination, and often ECG and imaging; NYHA class is based mainly on activity limitation caused by symptoms.3
Heart-failure symptoms, congestion, ejection fraction, and functional class can improve. Some underlying causes—such as a treatable rhythm problem, thyroid disorder, iron deficiency, uncontrolled blood pressure, or certain toxic exposures—may also be modifiable. Current expert terminology recognizes improvement, remission, and recovery as meaningful trajectories.1
Improvement does not necessarily mean that the prior diagnosis or long-term risk has disappeared. A person with previous symptomatic heart failure should not assume that they have returned to Stage A simply because symptoms lessen or ejection fraction improves. Continue follow-up, and make medication or treatment changes only with the treating clinician.
Heart failure blood tests are most useful when each one is tied to a clinical question. A natriuretic peptide may help assess whether cardiac strain could explain shortness of breath. Creatinine, electrolytes, and liver markers may show organ effects or provide treatment-safety context. CBC and iron studies may uncover anemia or iron deficiency that can worsen fatigue and exercise intolerance. Thyroid and metabolic tests may identify contributors or cardiovascular risk.
For a person diagnosed with heart failure, guideline-based initial laboratory evaluation commonly includes a CBC, urinalysis, serum electrolytes, blood urea nitrogen, creatinine, glucose, a fasting lipid profile, liver tests, iron studies, and thyroid-stimulating hormone. The exact selection depends on the person’s history, symptoms, medications, and suspected cause.4
Symptoms help determine urgency and which tests are appropriate. Common heart-failure symptoms include breathlessness during exertion or at rest, trouble breathing while lying flat, waking short of breath, ankle or leg swelling, abdominal fullness, fatigue, reduced stamina, persistent cough, and rapid weight gain from fluid.5
| Situation | Appropriate response |
|---|---|
| Severe or sudden symptoms | Call emergency services or seek emergency care for severe breathing difficulty, chest pressure or pain, fainting, confusion, blue or gray lips, or a sudden major decline. |
| New or worsening symptoms | Arrange prompt clinical evaluation. A clinician may use examination, ECG, chest imaging, echocardiography, and selected blood tests. |
| Stable risk-factor review | Outpatient testing may help assess blood pressure-related risk, diabetes, kidney health, lipids, thyroid function, anemia, or iron status. |
Risk is higher with coronary artery disease or prior heart injury, persistent hypertension, diabetes, obesity, chronic kidney disease, valve disease, cardiomyopathy, certain rhythm disorders, cardiotoxic exposure, sleep-disordered breathing, and family history. Risk factors do not prove heart failure; they show why a complete evaluation may be warranted.
The BNP test and NT-proBNP test measure related natriuretic peptides released when the heart experiences increased wall stress. In a person with compatible symptoms, an elevated value can support the possibility of heart failure and help guide the need for cardiac evaluation. A low value often makes heart failure less likely, but the result is not absolute.3
Natriuretic peptides can rise with reduced kidney function, atrial fibrillation, pulmonary hypertension, acute coronary syndromes, severe infection, and other cardiac or pulmonary stress. Values also tend to be higher with age. The clinical setting, assay, report range, and previous results all matter.
Obesity can suppress BNP and NT-proBNP concentrations. Symptoms may also arise before a value crosses a commonly used threshold, and preserved-ejection-fraction heart failure can be diagnostically challenging. A clinician may still need ECG, echocardiography, chest imaging, or other testing when the history and examination remain concerning.
The two tests come from the same hormone system but use different assays, units, decision thresholds, and biologic pathways. For trend monitoring, compare BNP with BNP or NT-proBNP with NT-proBNP whenever practical. Certain heart-failure medications can also affect BNP and NT-proBNP differently, so medication context belongs in the interpretation.
A complete blood count with differential and platelets measures red cells, hemoglobin, white cells, and platelets. Anemia can worsen breathlessness and fatigue; an unusual white-cell pattern may point toward infection or inflammation that deserves evaluation.
A comprehensive metabolic panel combines glucose, kidney-related markers, electrolytes, proteins, and liver-associated enzymes. It is a practical overview, but individual results still need to be interpreted separately. An albumin test, for example, can add context when swelling, nutrition, liver disease, kidney protein loss, or systemic illness is part of the differential.
The heart and kidneys continually influence one another. Reduced forward blood flow, venous congestion, changes in fluid balance, and treatment effects can alter kidney filtration. Chronic kidney disease can also increase cardiovascular risk and raise BNP or NT-proBNP independent of heart failure severity.6
Iron deficiency may reduce energy, exercise capacity, and quality of life in heart failure—even before hemoglobin falls enough to meet the definition of anemia. A panel containing iron, total iron-binding capacity, and ferritin allows calculation or reporting of transferrin saturation (TSAT) and gives a fuller view than ferritin alone.
Traditional heart-failure criteria have often defined iron deficiency as ferritin below 100 ng/mL, or ferritin 100–299 ng/mL with TSAT below 20%. Newer analyses suggest TSAT below 20% and serum iron may identify clinically meaningful deficiency more reliably than ferritin in some people with heart failure. This is an evolving area; use the laboratory’s units and reference information, and ask a clinician to interpret discordant results rather than self-treating with iron.7,8
When the anemia pattern or diet suggests another cause, targeted tests such as a vitamin B12 and folate panel may be appropriate. The broader CBC and anemia guide and iron-deficiency anemia guide explain how these patterns fit together.
Thyroid excess or deficiency can affect heart rate, rhythm, vascular resistance, fluid balance, and energy. A TSH and Free T4 test is often more informative than a thyroid marker considered in isolation. See the thyroid blood-test guide for pattern-based interpretation.
A glucose test and A1C test assess current and longer-term glycemic status. Diabetes is a major cardiovascular and kidney risk factor, but neither glucose nor A1C diagnoses heart failure. The diabetes and prediabetes guide covers diagnostic thresholds and follow-up.
A lipid panel helps assess atherosclerotic cardiovascular risk. An apolipoprotein B test can refine the estimate of atherogenic particle burden in selected situations. These markers help assess causes and comorbid risk; they do not measure congestion or assign a heart-failure stage.
Liver-associated enzymes, bilirubin, and albumin may change with congestion, low cardiac output, medication effects, or an unrelated liver condition. Interpret an abnormal result as a clue, not proof of a cardiac cause; the liver function test guide explains common patterns.
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are nonspecific inflammatory markers. They may be useful when infection, inflammatory disease, or another targeted question is present, but routine measurement does not diagnose heart failure.
| Laboratory testing can help | Laboratory testing cannot do alone |
|---|---|
| Support or weaken suspicion of cardiac wall stress | Confirm or exclude every form of heart failure |
| Identify anemia, iron deficiency, thyroid dysfunction, dysglycemia, or kidney disease | Show ejection fraction, valve function, chamber structure, or filling pressures |
| Assess electrolyte, kidney, and liver patterns that affect safety and monitoring | Assign ACC/AHA/HFSA stage or NYHA class |
| Track a marker over time when the same assay is used | Explain a change without considering symptoms, medications, timing, and clinical events |
An ECG evaluates electrical rhythm and conduction. Echocardiography evaluates cardiac structure, valves, pumping function, and aspects of filling. Chest imaging can assess the lungs and congestion. Depending on the suspected cause, a clinician may recommend stress testing, coronary imaging, cardiac MRI, sleep evaluation, or genetic assessment. These tools are selected for a reason; they are not routine for everyone.
Testing may be useful when a clinician is evaluating compatible symptoms, when established heart failure needs laboratory monitoring, or when cardiovascular risk factors warrant assessment before symptoms appear. Common scenarios include:
There is no universal fixed testing schedule for every person with heart failure. Timing depends on symptoms, disease stability, treatment changes, kidney function, previous abnormalities, and the clinician’s monitoring plan.
The safest testing plan starts with the question, not the largest available panel.
| Testing level | Typical role | Examples |
|---|---|---|
| Common first-line | Supports an initial, medically stable evaluation or establishes a baseline after diagnosis | One natriuretic peptide, CBC, kidney function, electrolytes, glucose, liver markers, urinalysis, iron studies, and TSH as clinically appropriate |
| Targeted follow-up | Investigates a specific symptom, abnormal pattern, suspected cause, or comorbidity | Free T4 after an abnormal TSH; ferritin and TSAT for suspected iron deficiency; A1C for dysglycemia; uACR for kidney risk |
| Monitoring | Checks a known issue or provides treatment-safety context | Kidney function and electrolytes after a clinician-directed treatment change; repeat CBC or iron studies after an identified abnormality |
| Specialist-directed | Evaluates complex, advanced, inherited, infiltrative, inflammatory, or otherwise unusual disease | Specialized biomarkers, genetics, or advanced imaging selected by cardiology or another specialist |
| Not broad routine screening | Avoids tests that lack a specific indication | Routine CK-MB, PT/INR, PTT, inflammatory panels, or genetic testing for every person with possible heart failure |
Start with the laboratory report, then add clinical context. A reference interval describes values observed in a laboratory’s reference population. A clinical decision threshold is a value studied for a particular use, such as ruling out a diagnosis in a specific setting. The two are not necessarily the same.
Preparation depends on the selected tests. BNP, NT-proBNP, CBC, and many kidney or electrolyte tests generally do not require fasting. A fasting lipid panel or glucose measurement may require a fasting interval when specifically ordered that way.
A heart attack is an acute loss of blood flow that injures heart muscle; heart failure is a clinical syndrome in which cardiac dysfunction produces symptoms, signs, or congestion. A heart attack can cause heart failure, but the terms are not interchangeable. Suspected heart attack symptoms require emergency care, not outpatient testing. Read the dedicated heart attack guide and the explanation of troponin I versus troponin T for more detail.
For medically stable questions, direct-access testing can help gather selected laboratory information before a clinician discussion or follow a clinician-recommended plan. Choose tests based on a defined question, follow the listed preparation instructions, and share the complete report—not only flagged values—with a qualified healthcare professional.
Direct-access testing cannot diagnose heart failure, assign a stage or NYHA class, interpret symptoms in real time, provide an ECG or echocardiogram, or manage advanced disease. If symptoms are new, severe, or rapidly worsening, seek medical care instead of ordering outpatient tests.
BNP or NT-proBNP is the blood test most directly associated with cardiac wall stress, but neither result confirms heart failure alone. Diagnosis requires compatible clinical findings and usually ECG and echocardiographic or other objective evidence.
No. A high BNP supports heart failure in the right setting but can also occur with kidney dysfunction, atrial fibrillation, older age, pulmonary disease, and other stress. Obesity may lower the value.
Usually, one natriuretic peptide is selected for the clinical question. The tests are related but not numerically interchangeable. Ordering both routinely rarely adds useful information.
ACC/AHA/HFSA Stage A is at risk for heart failure; Stage B is pre-heart failure; Stage C is symptomatic heart failure; and Stage D is advanced heart failure. The stages describe disease development and clinical status, not a BNP range.
NYHA Classes I–IV describe how much heart-failure symptoms limit physical activity, from no limitation with ordinary activity in Class I to symptoms that may occur at rest in Class IV. The clinician-assigned class can change as symptoms improve or worsen.
A low result can make heart failure less likely, especially in an appropriate diagnostic setting, but it does not end every evaluation. Obesity, timing, assay thresholds, and preserved-ejection-fraction presentations can complicate interpretation.
Heart and kidney function affect one another. Creatinine, eGFR, BUN, uACR, urinalysis, and electrolyte trends can reveal kidney disease, congestion-related effects, or treatment-safety concerns and can also help explain BNP or NT-proBNP levels.
Iron deficiency can affect exercise capacity even without anemia. Ferritin reflects storage but can rise with inflammation; transferrin saturation estimates circulating iron availability. Reading them with serum iron, TIBC, and CBC is more informative than using ferritin alone.
No. TSH, Free T4, glucose, A1C, lipids, and related tests can identify contributors or cardiovascular risk, but they do not show cardiac structure or establish heart failure.
BNP, NT-proBNP, CBC, and many kidney or electrolyte tests typically do not. Some lipid and glucose orders may require fasting. Follow the instructions for the exact tests ordered.
There is no fixed schedule for everyone. Repeat testing depends on symptoms, clinical stability, treatment changes, kidney function, previous abnormalities, and the treating clinician’s plan.
Symptoms, congestion, ejection fraction, and NYHA class can improve, and some causes are treatable. Improvement does not automatically erase the prior diagnosis or long-term risk, and treatment changes should be clinician-directed.
A BNP test for heart failure or an NT-proBNP result is one piece of evidence, not the entire diagnosis. Kidney function, electrolytes, CBC, iron status, thyroid function, glucose, lipids, liver markers, symptoms, examination findings, ECG, and imaging work together to clarify what is happening and what deserves attention.
Heart failure stages and NYHA functional classification add a second layer of context: stage describes the disease continuum, while class describes activity limitation. Neither comes from a single blood test. Use laboratory results to support informed clinical evaluation—not to delay urgent care, self-assign a stage, or change treatment on your own.
Editorial update: Originally published August 8, 2026. Updated August 28, 2026 to add heart failure stages and NYHA functional classification, update iron-status interpretation, strengthen internal links, and consolidate the legacy staging article.
Commercial disclosure: Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.
Common or first-line when clinically appropriate for compatible symptoms.
BNP and NT-proBNP answer related clinical questions, but their numerical results are not directly interchangeable.
Common or first-line testing.
Common baseline and monitoring tests.
Common, targeted, or follow-up testing depending on the blood-count pattern and history.
Risk-based, targeted, or monitoring tests.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
